首页> 外文期刊>Diagnostic pathology >Persistence of chloroquine-resistant haplotypes of Plasmodium falciparum in children with uncomplicated Malaria in Lagos, Nigeria, four years after change of chloroquine as first-line antimalarial medicine
【24h】

Persistence of chloroquine-resistant haplotypes of Plasmodium falciparum in children with uncomplicated Malaria in Lagos, Nigeria, four years after change of chloroquine as first-line antimalarial medicine

机译:氯喹改为第一线抗疟药后四年,尼日利亚拉各斯无疟疾儿童的恶性疟原虫抗氯喹单倍型持续存在

获取原文
           

摘要

Background In Nigeria, despite the change in National malaria drug policy to artemisinin combination therapy (ACT) in 2005 due to widespread chloroquine resistance, chloroquine (CQ) is still widely used in the treatment of malaria because it is cheap, affordable and accessible. The use of ACT for the management of uncomplicated malaria is currently being promoted. The employment of genetic markers to track circulating chloroquine-resistant parasites are useful in elucidating likely poor efficacy of chloroquine, especially in settings where it is not recommended for the treatment of uncomplicated falciparum malaria. This study determined the prevalence of pfcrt haplotypes and point mutations in pfmdr1 genes four years after the change in antimalarial treatment policy from CQ to the ACTs in Lagos, a commercial city in South-West, Nigeria. Methods This was a cross sectional study on uncomplicated malaria in children less than 12 years that presented with fever and other symptoms suggestive of malaria. Parasite DNA was extracted from 119 patients out of 251 children who were positive for Plasmodium falciparum by microscopy and amplified. The occurrence of haplotypes was investigated in pfcrt gene using probe-based qPCR and single nucleotide polymorphisms in pfmdr1 gene using nested PCR. Results One hundred and nine (109) of the 119 children with P falciparum infection (91.6%) harbourd parasites with the mutant pfcrt haplotype (CVIET). Out of this, 4.2% comprised a mixture of genotypes encoding CVMNK and CVIET, while 4.2% had the wild type (CVMNK). Furthermore, the frequency of point mutations in pfmdr1 was 62.2% and 69.0% for codons Y86 and F184 respectively. There were no mutations at codons 1034, 1042 and 1246 of the Pfmdr1 genes. Conclusion The high frequency of the CQ-resistant haplotypes (CVIET) and mutations in Pfmdr1 associated with CQ resistance in P. falciparum among these children suggest that CQ-resistant parasites are still in circulation. Continuous use of chloroquine may continue to increase the level of mutations in pfcrt and pfmdr1genes. There is need to strengthen current case management efforts at promoting ACT use as well as urgently restricting access to chloroquine by the National drug regulatory agency, National Agency for Food Drug Administration and Control (NAFDAC). Virtual Slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2069472010142303 webcite
机译:背景技术在尼日利亚,尽管由于广泛的氯喹耐药性,国家疟疾药物政策于2005年更改为青蒿素联合疗法(ACT),但氯喹(CQ)仍被广泛用于治疗疟疾,因为它价格便宜,负担得起且容易获得。目前正在推广使用ACT来管理简单的疟疾。使用遗传标记物追踪对氯喹耐药的循环寄生虫有助于阐明氯喹的不良疗效,特别是在不建议用于治疗单纯性恶性疟疾的地区。这项研究确定了在尼日利亚西南部商业城市拉各斯将抗疟疾治疗政策从CQ改为ACT四年后,pfmdr1基因中pfcrt单倍型和点突变的流行。方法这是一项横断面研究,对12岁以下且有发烧和其他疟疾症状的儿童进行简单疟疾研究。通过显微镜检查,从251名恶性疟原虫呈阳性的儿童中,从119名患者中提取了寄生虫DNA并进行了扩增。使用基于探针的qPCR研究了pfcrt基因中单倍​​型的发生,并使用巢式PCR研究了pfmdr1基因中的单核苷酸多态性。结果119例恶性疟原虫感染患儿中有一百零九(109)个(91.6%)携带突变型pfcrt单倍型(CVIET)感染了港口寄生虫。其中4.2%包含编码CVMNK和CVIET的基因型的混合物,而4.2%具有野生型(CVMNK)。此外,对于密码子Y86和F184,pfmdr1中点突变的频率分别为62.2%和69.0%。 Pfmdr1基因的密码子1034、1042和1246没有突变。结论这些儿童中恶性疟原虫的耐CQ单倍型(CVIET)和Pfmdr1突变与恶性疟原虫的CQ抗性相关,表明CQ抗性寄生虫仍在传播。连续使用氯喹可能会继续增加pfcrt和pfmdr1基因的突变水平。有必要加强当前的病例管理工作,以促进ACT的使用以及国家药品监管机构,国家食品药品监督管理局(NAFDAC)紧急限制氯喹的获取。虚拟幻灯片可以在这里找到本文的虚拟幻灯片:http://www.diagnosticpathology.diagnomx.eu/vs/2069472010142303 webcite

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号